Literature DB >> 22459152

The novel chromogranin A-derived serpinin and pyroglutaminated serpinin peptides are positive cardiac β-adrenergic-like inotropes.

Bruno Tota1, Stefano Gentile, Teresa Pasqua, Eleonora Bassino, Hisatsugu Koshimizu, Niamh X Cawley, Maria C Cerra, Y Peng Loh, Tommaso Angelone.   

Abstract

Three forms of serpinin peptides, serpinin (Ala26Leu), pyroglutaminated (pGlu)-serpinin (pGlu23Leu), and serpinin-Arg-Arg-Gly (Ala29Gly), are derived from cleavage at pairs of basic residues in the highly conserved C terminus of chromogranin A (CgA). Serpinin induces PN-1 expression in neuroendocrine cells to up-regulate granule biogenesis via a cAMP-protein kinase A-Sp1 pathway, while pGlu-serpinin inhibits cell death. The aim of this study was to test the hypothesis that serpinin peptides are produced in the heart and act as novel β-adrenergic-like cardiac modulators. We detected serpinin peptides in the rat heart by HPLC and ELISA methods. The peptides included predominantly Ala29Gly and pGlu-serpinin and a small amount of serpinin. Using the Langendorff perfused rat heart to evaluate the hemodynamic changes, we found that serpinin and pGlu-serpinin exert dose-dependent positive inotropic and lusitropic effects at 11-165 nM, within the first 5 min after administration. The pGlu-serpinin-induced contractility is more potent than that of serpinin, starting from 1 nM. Using the isolated rat papillary muscle preparation to measure contractility in terms of tension development and muscle length, we further corroborated the pGlu-serpinin-induced positive inotropism. Ala29Gly was unable to affect myocardial performance. Both pGlu-serpinin and serpinin act through a β1-adrenergic receptor/adenylate cyclase/cAMP/PKA pathway, indicating that, contrary to the β-blocking profile of the other CgA-derived cardiosuppressive peptides, vasostatin-1 and catestatin, these two C-terminal peptides act as β-adrenergic-like agonists. In cardiac tissue extracts, pGlu-serpinin increased intracellular cAMP levels and phosphorylation of phospholamban (PLN)Ser16, ERK1/2, and GSK-3β. Serpinin and pGlu-serpinin peptides emerge as novel β-adrenergic inotropic and lusitropic modulators, suggesting that CgA and the other derived cardioactive peptides can play a key role in how the myocardium orchestrates its complex response to sympathochromaffin stimulation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22459152      PMCID: PMC3382102          DOI: 10.1096/fj.11-201111

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  40 in total

1.  Equilibrium between adenylyl cyclase and phosphodiesterase patterns adrenergic agonist dose-dependent spatiotemporal cAMP/protein kinase A activities in cardiomyocytes.

Authors:  Vania De Arcangelis; Shubai Liu; Dawen Zhang; Dagoberto Soto; Yang K Xiang
Journal:  Mol Pharmacol       Date:  2010-06-07       Impact factor: 4.436

2.  Role of reactive oxygen species in hyperadrenergic hypertension: biochemical, physiological, and pharmacological evidence from targeted ablation of the chromogranin a (Chga) gene.

Authors:  Jiaur R Gayen; Kuixing Zhang; Satish P RamachandraRao; Manjula Mahata; Yuqing Chen; Hyung-Suk Kim; Robert K Naviaux; Kumar Sharma; Sushil K Mahata; Daniel T O'Connor
Journal:  Circ Cardiovasc Genet       Date:  2010-08-20

Review 3.  The interplay between chromogranin A-derived peptides and cardiac natriuretic peptides in cardioprotection against catecholamine-evoked stress.

Authors:  Rosa Mazza; Sandra Imbrogno; Bruno Tota
Journal:  Regul Pept       Date:  2010-06-08

4.  Serpinin: a novel chromogranin A-derived, secreted peptide up-regulates protease nexin-1 expression and granule biogenesis in endocrine cells.

Authors:  Hisatsugu Koshimizu; Niamh X Cawley; Taeyoon Kim; Alfred L Yergey; Y Peng Loh
Journal:  Mol Endocrinol       Date:  2011-03-24

Review 5.  Catecholamines, cardiac natriuretic peptides and chromogranin A: evolution and physiopathology of a 'whip-brake' system of the endocrine heart.

Authors:  Bruno Tota; Maria Carmela Cerra; Alfonsina Gattuso
Journal:  J Exp Biol       Date:  2010-09-15       Impact factor: 3.312

Review 6.  Neuropeptidomic components generated by proteomic functions in secretory vesicles for cell-cell communication.

Authors:  Vivian Hook; Steven Bark; Nitin Gupta; Mark Lortie; Weiya D Lu; Nuno Bandeira; Lydiane Funkelstein; Jill Wegrzyn; Daniel T O'Connor; Pavel Pevzner
Journal:  AAPS J       Date:  2010-08-24       Impact factor: 4.009

7.  PKA, Rap1, ERK1/2, and p90RSK mediate PGE2 and EP4 signaling in neonatal ventricular myocytes.

Authors:  Quan He; Pamela Harding; Margot C LaPointe
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-10-30       Impact factor: 4.733

8.  Postconditioning induces an anti-apoptotic effect and preserves mitochondrial integrity in isolated rat hearts.

Authors:  Claudia Penna; Maria-Giulia Perrelli; Stefania Raimondo; Francesca Tullio; Annalisa Merlino; Francesca Moro; Stefano Geuna; Daniele Mancardi; Pasquale Pagliaro
Journal:  Biochim Biophys Acta       Date:  2009-03-26

9.  Chromogranin/secretogranin proteins in murine heart: myocardial production of chromogranin A fragment catestatin (Chga(364-384)).

Authors:  Nilima Biswas; Erica Curello; Daniel T O'Connor; Sushil K Mahata
Journal:  Cell Tissue Res       Date:  2010-11-05       Impact factor: 5.249

10.  Selective attenuation of norepinephrine release and stress-induced heart rate increase by partial adenosine A1 agonism.

Authors:  Lorenz Bott-Flügel; Alexandra Bernshausen; Heike Schneider; Peter Luppa; Katja Zimmermann; Barbara Albrecht-Küpper; Raimund Kast; Karl-Ludwig Laugwitz; Heimo Ehmke; Andreas Knorr; Melchior Seyfarth
Journal:  PLoS One       Date:  2011-03-28       Impact factor: 3.240

View more
  21 in total

1.  A haplotype variant of the human chromogranin A gene (CHGA) promoter increases CHGA expression and the risk for cardiometabolic disorders.

Authors:  Lakshmi Subramanian; Abrar A Khan; Prasanna K R Allu; Malapaka Kiranmayi; Bhavani S Sahu; Saurabh Sharma; Madhu Khullar; Ajit S Mullasari; Nitish R Mahapatra
Journal:  J Biol Chem       Date:  2017-06-30       Impact factor: 5.157

Review 2.  Chromogranin A and derived peptides in health and disease.

Authors:  Y Peng Loh; Yong Cheng; Sushil K Mahata; Angelo Corti; Bruno Tota
Journal:  J Mol Neurosci       Date:  2012-03-03       Impact factor: 3.444

3.  Muscle injury, impaired muscle function and insulin resistance in Chromogranin A-knockout mice.

Authors:  Kechun Tang; Teresa Pasqua; Angshuman Biswas; Sumana Mahata; Jennifer Tang; Alisa Tang; Gautam K Bandyopadhyay; Amiya P Sinha-Hikim; Nai-Wen Chi; Nicholas J G Webster; Angelo Corti; Sushil K Mahata
Journal:  J Endocrinol       Date:  2016-10-31       Impact factor: 4.286

Review 4.  Chromogranins: from discovery to current times.

Authors:  Karen B Helle; Marie-Helene Metz-Boutigue; Maria Carmela Cerra; Tommaso Angelone
Journal:  Pflugers Arch       Date:  2017-09-05       Impact factor: 3.657

Review 5.  Chromogranin A: a paradoxical player in angiogenesis and vascular biology.

Authors:  Karen B Helle; Angelo Corti
Journal:  Cell Mol Life Sci       Date:  2014-10-09       Impact factor: 9.261

6.  Impact of Chromogranin A deficiency on catecholamine storage, catecholamine granule morphology and chromaffin cell energy metabolism in vivo.

Authors:  Teresa Pasqua; Sumana Mahata; Gautam K Bandyopadhyay; Angshuman Biswas; Guy A Perkins; Amiya P Sinha-Hikim; David S Goldstein; Lee E Eiden; Sushil K Mahata
Journal:  Cell Tissue Res       Date:  2015-11-16       Impact factor: 5.249

7.  Serpinins: role in granule biogenesis, inhibition of cell death and cardiac function.

Authors:  Y P Loh; H Koshimizu; N X Cawley; B Tota
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

8.  pGlu-serpinin protects the normotensive and hypertensive heart from ischemic injury.

Authors:  T Pasqua; B Tota; C Penna; A Corti; M C Cerra; P Loh Y; T Angelone
Journal:  J Endocrinol       Date:  2015-09-23       Impact factor: 4.286

9.  Functional genetic variants of the catecholamine-release-inhibitory peptide catestatin in an Indian population: allele-specific effects on metabolic traits.

Authors:  Bhavani S Sahu; Jagan M Obbineni; Giriraj Sahu; Prasanna K R Allu; Lakshmi Subramanian; Parshuram J Sonawane; Pradeep K Singh; Binu K Sasi; Sanjib Senapati; Samir K Maji; Amal K Bera; Balashankar S Gomathi; Ajit S Mullasari; Nitish R Mahapatra
Journal:  J Biol Chem       Date:  2012-10-26       Impact factor: 5.157

Review 10.  Glycosylated Chromogranin A: Potential Role in the Pathogenesis of Heart Failure.

Authors:  Anett H Ottesen; Geir Christensen; Torbjørn Omland; Helge Røsjø
Journal:  Curr Heart Fail Rep       Date:  2017-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.